source
- FDA grants accelerated approval for Etcamah combo therapy for advanced HR-positive, HER2-negative breast cancerThe U.S. Food and Drug Administration announced accelerated approval of Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adult patients with hormone-receptor-positive, HER2-negativ…
- Medline expands recall of reprocessed electrophysiology and ultrasound catheters due to contamination riskMedline Industries has issued an expanded recall that adds new lots of reprocessed electrophysiology and ultrasound catheters after the FDA identified possible residual particulates in the devices.…